Development of drug resistance mutations in patients on highly active antiretroviral therapy: Does competitive advantage drive evolution

AIDS Reviews

Volumn 9, Issue 2, 2007, Pages 68-74

  Kolber, Michael A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Resistance mutations; Viral evolution; Viral fitness

Indexed keywords

ALANINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARAGINE; ASPARTIC ACID; EFAVIRENZ; GAG PROTEIN; GLUTAMINE; GLYCINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; POL PROTEIN; PROLINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE; VALINE; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ZIDOVUDINE;

DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PATIENT COMPLIANCE; QUALITY OF LIFE; REBOUND; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SURVIVAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; VIRAL LOAD;

EID: 34547493264     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Rouzine I, Rodrigo A, Coffin J. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev 2001;65:151-85.
2. Shankarappa R, Margolick J, Gange S, et al. Consistent viral evolutionary changes associated with the progression of HIV-1 infection. J Virol 1999;73:10489-502.
3. Gunthard H, Wong J, Ignacio C, et al. HIV replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-8.
4. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006;20:985-93.
5. Iyengar S, Chin B, Margolick J, Sabundayo B, Schwartz D. Anatomical loci of HIV-associated immune activation and association with viremia. Lancet 2003;362:945-50.
6. Mohri H, Perelson A, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy, J Exp Med 2001;194:1277-87.
7. Benito J, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:227-33.
8. Cohen Stuart J, Hazenberg M, Hamann D, et al. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000;25:203-11.
9. Martinez E, Arnedo M, Giner V, et al. Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 2001;15:1477-82.
10. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogs alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999;13:F1-8.
11. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual HIV-1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/ml. J Infect Dis 1998;177:235-8.
12. Dybul M, Chun T, Ward D, et al. Evaluation of lymph node virus burden in HIV-infected patients receiving efavirenz-based protease inhibitor-sparing HAART. J Infect Dis 2000;181:1273-9.
13. Martinez M, Cabana M, Ibanez A, Clotet B, Arno A, Ruiz L. HIV-1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999;256:180-7.
14. Kantor R, Shafer R, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004;18:1503-11.
15. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron J. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005;40:34-40.
16. Kristiansen T, Pedersen A, Eugen-Olsen J, Katzenstein T, Lundgren J. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand J Infect Dis 2005;37:890-901.
17. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen Clin Infect Dis 2006;43:1329-36.
18. Fu Y. Estimating mutation rate and generation time from longitudinal samples of DNA sequences. Mol Biol Evol 2001;18:620-6.
19. Barbour J, Wrin T, Grant R, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in HIV-infected adults. J Virol 2002;76:11104-12.
20. Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003;69:1-6.
21. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002;16:1967-9.
22. Moore A, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on HAART: transient increase or treatment failure? AIDS 2002;16:615-8.
23. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during HAART. J Virol 2003;77:12165-72.
24. Nettles R, Kieffer T, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-29.
25. Simpson G. Tempo and Mode in Evolution. New York: Columbia Univ Press 1944.
26. Raboud J, Rae S, Woods R, Harris M, Montaner J. INCAS and AVANTI Study Groups. Consecutive rebounds in plasma viral load are associated with virologic failure at 52 weeks among HIV-infected patients. AIDS 2002;16:1627-32.
27. Nettles R, Kieffer T, Simmons R, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving HAART. Clin Infect Dis 2004;39:1030-7.
28. Sungkanuparph S, Groger R, Overton E, Fraser V, Powderly W. Persistent low-level viremia and virologic failure in HIV-1-infected patients treated with HAART. HIV Med 2006;7:437-41.
29. Gunthard H, Frost S, Leigh-Brown A, et al. Evolution of envelope sequences of HIV-1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-12.
30. Tobin N, Learn G, Holte S, et al. Evidence that low-level viremia during effective HAART result from two processes: expression of archival virus and replication of virus. J Virol 2005;79:9625-34
31. Frenkel L, Wang Y, Learn G, et al. Multiple viral genetic analyses detect low-level HIV-1 replication during effective HAART. J Virol 2003;77:5721-30.
32. Bailey J, Sedaghat A, Kieffer T, et al. Residual HIV-1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T-cells. J Virol 2006;80:6441-57.
33. Briones C, de Vicente A, Molina-Paris C, Domingo E. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene 2006;384:129-38.
34. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ. Extensive recombination among HIV-1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 2006;80:2472-82.
35. Wolinsky S, Korber B, Neumann A, et al. Adaptive evolution of HIV-1 during the natural course of infection. Science 1996;272:537-42.
36. Delwart E, Pan H, Neumann A, Markowitz M. Rapid, transient changes at the env locus of plasma HIV-1 populations during the emergence of protease inhibitor resistance. J Virol 1998;72: 2416-21.
37. Fernandez G, Clotet B, Martinez M. Fitness landscape of HIV-1 protease quasispecies. J Virol 2007;81:2485-96.
38. Foulkes A, De Gruttola V. Characterizing the progression of viral mutations over time. J Am Stat Ass 2003;98:859-67.
39. Beerenwinkel N, Daumer M, Sing T, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005;191:1953-60.
40. Bacheler L, Anton E, Kudish P, et al. HIV-1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-84.
41. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing NNRTI therapy. J Virol 2001;75:4999-5008.
42. Wang J, Dykes C, Domaoal R, Koval C, Bambara R, Demeter L. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to NNRTI, demonstrate reductions in RNaseH activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 2006;348:462-74.
43. Koval C, Dykes C, Wang J, Demeter L. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L1001 by the nucleoside resistance mutation L74V. Virology 2006;353:184-92.
44. Bangsberg D. Less than 95% adherence to NNRTI therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41.
45. Maguire M, Guinea R, Griffin P, et al. Changes in HIV-1 Gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002;76:7398-406.
46. Borman A, Paulous S, Clavel F. Resistance of HIV-1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996;77:419-26.
47. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of HIV-1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000;74:8524-31.
48. Garcia-Lerma J, MacInnes H, Bennett D, Weinstock H, Heneine W. Transmitted HIV-1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 2004;78:7545-52.
49. Lech W, Wang G, Yang Y, et al. In vivo sequence diversity of the protease of HIV-1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-43.
50. Quiros-Roldan E, Moretti F, Torti C, Tirelli V, Casari S, Carosi G. HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens. J Clin Lab Anal 2005;19:26-9.
51. Karlsson A, Deeks S, Barbour J, et al. Dual pressure from antiretroviral therapy and cell-mediated immune response on the HIV-1 protease gene. J Virol 2003;77:6743-52.
52. Schmitt M, Harrer E, Goldwich A, et al. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000;14:653-8.
53. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-8.